

Only for internal understanding/Swan

Date of start observation	GICS sector		CCC to AAA	ESG Rating (MSCI)	Global Compliance Rating (Sustainalytics)	Principle at risk	1= Low, 5=High Highest Controversy Level (Sustainalytics)	Expected results and timeline	Latest update/review		
Date	SecurityName	ISIN	Sector					Case assessment	Actions	Outlook	Case review date
05/02/2023	Contra Abiomed Inc Rights	US003CVR0169	Health Care Equipment	A	Watchlist	1 - Human Rights	4	This is a CVR (Contingent Value Right) - those are not-tradeable. These rights resulted out of the takeover of Abiomed by JNJ end-2022. Whereas Abiomed had no breaches of any UN Global Compact principles, JNJ (the acquirer) was on observation list by Sustainalytics, a data provider, for breaching Human Rights principles. JNJ's poor ratings (not Abiomed's good ratings) were transferred to the Rights received, leading to this "passive breach".	Awaiting rights to expire, hopefully with the extra payment as milestones are achieved. It is not possible to sell the position.	The Rights are non-tradeable and therefore cannot be sold out. We have no information of the time line for the relevant triggers. According to company homepage, these rights entitle the holder to receive up to \$35 per share in cash if certain commercial and clinical milestones are achieved. See more information about the acquisition in the link below.	05/02/2023

<https://www.abiomed.com/about-us/news-and-media/press-releases/johnson-and-johnson-completes-acquisition-of-abiomed>